問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of General Surgery

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

劉建廷
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

82Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉建廷

List

168Cases

2020-01-01 - 2029-12-31

Phase III

Active
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma (ESCC)、 Gastroesophageal Junction Carcinoma (GEJC)、 Esophageal Adenocarcinoma (EAC)

  • Test Drug

    Pembrolizumab (MK-3475) KEYTRUDA®

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2020-06-01 - 2029-12-31

Phase II

Active
A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)

  • Condition/Disease

    Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

  • Test Drug

    Pembrolizumab (MK-3475)/ Lenvatinib (E7080/MK-7902)

Participate Sites
7Sites

Recruiting7Sites

2021-03-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2022-12-15 - 2027-12-31

Phase I/II

Active
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    Lenvima capsule 4 mgR/ Lenvima capsule 4 mgR KeytrudaR/ KeytrudaR Lenvima capsule 10 mgR/ Lenvima capsule 10 mgRMK-4830 IntaxelR Cancer Treatment Intravenous Infusion Concentrate/ IrinotelR

Participate Sites
7Sites

Recruiting7Sites

2016-12-15 - 2020-06-08

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

白禮源
China Medical University Hospital-Taipei

未分科

2020-03-01 - 2026-12-31

Phase III

Active
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

  • Condition/Disease

    Advanced Renal Cell Carcinoma

  • Test Drug

    MK-6482 R/AfinitorR

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2022-05-02 - 2023-04-18

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-03-01 - 2024-12-26

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2021-10-01 - 2022-08-24

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2015-05-01 - 2018-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 5 6 7 8 9 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB